Loading insider details...
Beta
Latest Form 4 (Jun 26, 2026): Grant/Award of 45,000 CNTX shares.
Every alert includes an AI-written analysis of the filing, plus news and market context.
| Filed | Company | Transaction | Shares | Value |
|---|---|---|---|---|
| Jun 26, 2026 | Context Therapeutics Inc. (CNTX) | Grant/Award | 45,000 | n/a |
| Jun 18, 2026 | Zentalis Pharmaceuticals, Inc. (ZNTL) | Grant/Award | 57,100 | n/a |
| Jun 18, 2025 | Zentalis Pharmaceuticals, Inc. (ZNTL) | Grant/Award | 57,603 | n/a |
| Jun 12, 2025 | Context Therapeutics Inc. (CNTX) | Grant/Award | 123,500 | n/a |
| Feb 4, 2025 | Zentalis Pharmaceuticals, Inc. (ZNTL) | Purchase | 14,200 | $25.0K |
| Sep 5, 2024 | Context Therapeutics Inc. (CNTX) | Grant/Award | 19,315 | n/a |
| May 29, 2024 | Zentalis Pharmaceuticals, Inc. (ZNTL) | Grant/Award | 72,481 | n/a |
| Mar 11, 2024 | Harpoon Therapeutics, Inc. (HARP) | Disposition to Issuer | 135,000 | n/a |
| Jan 9, 2024 | Harpoon Therapeutics, Inc. (HARP) | Grant/Award | 115,000 | n/a |